Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-20T20:00:49.249Z Has data issue: false hasContentIssue false

Cardiovascular benefits of lycopene: fantasy or reality?

Published online by Cambridge University Press:  09 September 2016

Frank Thies*
School of Medicine, Medical Sciences & Nutrition, Rowett Research Institute of Nutrition & Health, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
Lynsey M. Mills
School of Medicine, Medical Sciences & Nutrition, Rowett Research Institute of Nutrition & Health, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
Susan Moir
School of Medicine, Medical Sciences & Nutrition, Rowett Research Institute of Nutrition & Health, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
Lindsey F. Masson
School of Pharmacy and Life Sciences, Robert Gordon University, Garthdee Road, Aberdeen AB10 7GJ, UK
*Corresponding author: F. Thies, email
Rights & Permissions [Opens in a new window]


Epidemiological evidence indicates that high consumption of tomatoes and tomato-based products reduces the risk of chronic diseases such as CVD and cancer. Such potential benefits are often ascribed to high concentrations of lycopene present in tomato products. Mainly from the results of in vitro studies, potential biological mechanisms by which carotenoids could protect against heart disease and cancer have been suggested. These include cholesterol reduction, inhibition of oxidation processes, modulation of inflammatory markers, enhanced intercellular communication, inhibition of tumourigenesis and induction of apoptosis, metabolism to retinoids and antiangiogenic effects. However, with regard to CVD, results from intervention studies gave mixed results. Over fifty human intervention trials with lycopene supplements or tomato-based products have been conducted to date, the majority being underpowered. Many showed some beneficial effects but mostly on non-established cardiovascular risk markers such as lipid peroxidation, DNA oxidative damage, platelet activation and inflammatory markers. Only a few studies showed improvement in lipid profiles, C reactive protein and blood pressure. However, recent findings indicate that lycopene could exert cardiovascular protection by lowering HDL-associated inflammation, as well as by modulating HDL functionality towards an antiatherogenic phenotype. Furthermore, in vitro studies indicate that lycopene could modulate T lymphocyte activity, which would also inhibit atherogenic processes and confer cardiovascular protection. These findings also suggest that HDL functionality deserves further consideration as a potential early marker for CVD risk, modifiable by dietary factors such as lycopene.

Conference on ‘Phytochemicals and health: new perspectives on plant-based nutrition’
Copyright © The Authors 2016 

Results from observational studies suggest that high consumption of fruit and vegetables reduces the risk of chronic diseases such as CVD and cancer( Reference Trichopoulou, Costacou and Bamia 1 Reference Nicklett, Semba and Xue 3 ). A recent meta-analysis of sixteen prospective cohort studies including over 800 000 participants concluded that a higher consumption of fruit and vegetables is associated with a lower risk of mortality, particularly from CVD( Reference Wang, Ouyang and Liu 4 ). The results indicated that, for the consumption of up to five servings/d, the risk of cardiovascular mortality was decreased by 4 % for each additional daily serving of fruit and vegetables, and by 5 and 4 % for each additional daily serving of fruit and vegetables, respectively. However, the actual components of these foods that confer the protective effect and the mechanisms by which they act have yet to be firmly identified. Potential candidate chemical compounds include carotenoids, which represent a large family of over 700 hydrophobic red, orange and yellow pigments abundant in fruit and vegetables. However, only six of them (lycopene, α- and β-carotenes, β-cryptoxanthin, zeaxanthin and lutein) are found predominantly in human serum and constitute over 95 % of total circulating carotenoids( Reference Maiani, Casto´n and Catasta 5 ).

Much interest in recent years has focused on tomato-rich diets and lycopene, since observational studies associated high lycopene intake with reduced risk of prostate cancer( Reference Zu, Mucci and Rosner 6 Reference Giovannucci, Rimm and Liu 8 ). High consumption of tomato-rich diets (seven or more servings/week) has also been associated with a 30 % reduction in relative risk of CVD( Reference Sesso, Liu and Gaziano 9 ). Such potential benefits to vascular health from a tomato-rich diet are often ascribed to high concentrations of lycopene present in the fruit, as tomato products usually account for the majority of the dietary intake of this carotenoid( Reference Clinton 10 , Reference Rao, Ray and Rao 11 ). Blood lycopene concentrations are strongly associated with tomato intake( Reference Ganji and Kafai 12 Reference Re, Mishra and Thane 14 ). Lycopene is the most abundant carotenoid present in serum in the American population( Reference Erdman, Ford and Lindshield 15 ) and the second contributor to total serum carotenoids in Europeans( Reference Jenab, Ferrari and Mazuir 16 ). Nevertheless, serum concentrations are usually low and below 0·3 mg/ml( Reference Erdman, Ford and Lindshield 15 ). Based on the results mainly obtained from in vitro studies and animal models, potential biological mechanisms by which lycopene could protect against heart disease and cancer have been suggested. These include cholesterol reduction, inhibition of oxidation processes, modulation of inflammatory markers, enhanced intercellular communication, inhibition of tumourigenesis and induction of apoptosis, metabolism to retinoids and antiangiogenic effects( Reference Friedman 17 ). However, with regard to CVD, the results from intervention studies have given mixed results. The present paper reviews the evidence for the health benefits of high lycopene intake, and proposes the integration of novel mechanisms by which lycopene could confer cardiovascular protection.

Lycopene sources, structure, intake and bioavailability

Lycopene is a symmetrical tetraterpene comprising eight isoprene units. It is non-provitamin A carotenoid with very potent antioxidant properties due to its ability to efficiently quench singlet oxygen species( Reference Di Mascio, Kaiser and Sies 18 ) and hypochlorous acid( Reference Pennathur, Maitra and Byun 19 ). Tomato and tomato-based products are the main dietary source of lycopene and account for over 80 % of lycopene intake in western countries, but watermelon, pink grapefruit, apricot, pink guava and papaya also significantly contribute to lycopene intake( Reference Maiani, Casto´n and Catasta 5 ). Dietary intake of lycopene varies greatly depending on the populations considered. Median intake in the UK is about 1 mg/d( Reference Porrini and Riso 20 , Reference Thies, Masson and Rudd 21 ), while estimated intakes in American and Italian populations are over 7 mg/d( Reference Jacques, Lyass and Massaro 22 , Reference Lucarini, Lanzi and D'Evoli 23 ).

Lycopene occurs naturally mainly as all-trans isomer( Reference Schierle, Bretzel and Buhler 24 ), whereas cis isomers are the most abundant form in plasma and tissues( Reference Allen, Schwartz and Craft 13 , Reference Walfisch, Walfisch and Agbaria 25 ). Isomerisation occurs during food preparation and processing, as well as physiologically during digestion and absorption, which could impact on bioavailability( Reference Burton-Freeman and Sesso 26 ). However, many uncertainties remain with regard to lycopene metabolism. The process of trans-to-cis isomerisation can occur in the stomach( Reference Re, Fraser and Long 27 ), enterocytes( Reference Richelle, Sanchez and Tavazzi 28 ) and liver( Reference Teodoro, Perrone and Martucci 29 ). Intestinal absorption of lycopene is facilitated by scavenger receptor B1( Reference Moussa, Landrier and Reboul 30 ) and CD36( Reference Moussa, Gouranton and Gleize 31 ). Partial metabolisation can occur in the enterocyte via the action of two enzymes, β-carotene 15,15′-oxygenase-1, which has been associated with blood lycopene status( Reference Ferrucci, Perry and Matteini 32 ) and β-carotene-9,10′ oxygenase-2( Reference Lindshield, Canene-Adams and Erdman 33 ).

Due to the difficulty of producing labelled lycopene molecules, few tracer studies have been carried out to date. An accelerator MS study using 14C-labelled lycopene (92 % trans lycopene) showed that all trans lycopene was extensively isomerised (5-, 9-, 13- and 15-cis lycopene isomers) after dosing and rapidly metabolised into polar metabolites excreted into urine( Reference Ross, Vuong le and Ruckle 34 ). The rapid excretion of 14CO2 found in that study also suggested that part of the lycopene ingested was quickly fully oxidised. A recent compartmental modelling study using 13C-labelled lycopene found no differences between the bioavailability of cis- and all-trans lycopenes (24·5 v. 23·2 %, respectively). However, the study revealed that postabsorptive trans-to-cis isomerisation influences tissue and plasma isomeric profiles( Reference Moran, Cichon and Riedl 35 ). The half-life of plasma lycopene was originally estimated to range between 12 and 33 d( Reference Rock, Swendseid and Jacob 36 ). However, the latest tracer study showed half-lives of 5·3 and 8·8 d for all-trans and cis isomers, respectively( Reference Moran, Cichon and Riedl 35 ).

Interindividual variability in lycopene bioavailability is at least partly genetically controlled and has been linked to a combination of twenty-eight SNP in sixteen genes involved in lycopene and lipid metabolism( Reference Borel, Desmarchelier and Nowicki 37 ). Another recent study examined the association between variation across the genome (over seven million SNP included) and serum concentrations of lycopene in a multiethnic population involving 2581 post-menopausal women( Reference Zubair, Kooperberg and Liu 38 ). The study identified three novel loci (SCARB1, DHRS2 and SLIT3) associated with serum lycopene concentrations, the last two being specific to African Americans. These findings could perhaps explain the interindividual variability in physiological responses to increased lycopene intake frequently observed in human subjects.

Observational studies

The majority of epidemiological evidence suggests that serum lycopene concentration is inversely associated with CVD risk( Reference Rissanen, Voutilainen and Nyyssonen 39 Reference Yeo, Kim and Lim 41 ). More recently, high serum concentrations of carotenoids, including lycopene, have been inversely associated in middle-aged men with lower intima-media thickness, suggesting that high serum lycopene concentrations could protect against early atherosclerosis( Reference Karppi, Kurl and Ronkainen 42 ). Results from the same study showed that in men within the highest quartile of serum lycopene concentration, the risk of ischaemic stroke and any stroke was reduced by 59 and 55 % respectively compared with the lowest quartile( Reference Karppi, Laukkanen and Sivenius 43 ). Results from the 2003–2006 National Health and Nutrition Examination Survey showed similar associations with biomarkers of CVD risk such as LDL-cholesterol, homocysteine and C-reactive protein (CRP) concentration( Reference Wang, Chung and McCullough 44 ). However, studies assessing dietary intake of lycopene usually showed no association between dietary intake and CVD risk( Reference Sesso, Liu and Gaziano 9 , Reference Ascherio, Rimm and Hernan 45 Reference Tavani, Gallus and Negri 48 ). These findings are supported by the results of a recent meta-analysis of prospective studies on lycopene intake and serum concentrations and the risk of stroke, which showed that circulating concentrations of lycopene, but not dietary lycopene, was associated with a significant decrease in the risk of stroke( Reference Li and Xu 49 ). Such discrepancy between dietary intakes and serum concentrations could be linked to genetic variability modifying lycopene absorption. However, it has also been attributed at least partly to misclassification of lycopene intakes( Reference Jacques, Lyass and Massaro 22 ). When compensating for this potential issue by using repeated measures of intake obtained over a 10-year period, lycopene intake was found to be significantly inversely associated with CHD incidence( Reference Jacques, Lyass and Massaro 22 ).

Mechanistic studies

The discovery of mechanisms (Fig. 1) by which lycopene and derivatives can modulate cellular activity mainly originated from the extensive work carried out in cancer cells, and can be partially related to the antioxidant properties of lycopene( Reference Kelkel, Schumacher and Dicato 50 ). These mechanisms have been recently reviewed( Reference Friedman 17 , Reference Feitelson, Arzumanyan and Kulathinal 51 ), and include induction of apoptosis( Reference Amir, Karas and Giat 52 , Reference Gupta, Bansal and Koul 53 ) and inhibition of cell proliferation involving the modulation of the expression of genes involved in the phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B and mitogen-activated protein kinases signalling pathways as well as genes involved in the regulation of the cell cycle( Reference Uppala, Dissmore and Lau 54 Reference Chalabi, Delort and Le Corre 56 ). The induction of cell differentiation( Reference Amir, Karas and Giat 52 ) via the restoration of gap junctions( Reference Stahl, von Laar and Martin 57 ) has also been suggested. Other mechanisms include prevention of oxidative damage( Reference Palozza, Simone and Catalano 58 , Reference Palozza, Simone and Catalano 59 ), inhibition of angiogenesis( Reference Palozza, Simone and Catalano 59 , Reference Chen, Lin and Yang 60 ), induction of phase II enzymes( Reference Huang, Chuang and Lo 61 Reference Sahin, Tuzcu and Sahin 63 ), interaction with growth factors and sex hormones( Reference Linnewiel, Ernst and Caris-Veyrat 64 ) and the induction of nuclear receptors activation( Reference Herzog, Siler and Spitzer 65 Reference Tan, Moran and Cichon 67 ). Lycopene has also been found to confer photoprotection( Reference Stahl and Sies 68 ). Interestingly, it has been recently shown that lycopene, via bioactive metabolites, possesses partial pro-vitamin A activity transmitted via retinoic acid receptor-mediated signalling in mice( Reference Aydemir, Kasiri and Bartók 69 ).

Fig. 1. Potential mechanisms by which lycopene can modulate cellular activity.

Many studies using cellular models relevant to atherosclerosis have also been used in recent years, and a scheme integrating the potential cellular mechanisms by which lycopene could modulate atherosclerotic processes has been proposed( Reference Palozza, Parrone and Simone 70 ). Vascular endothelial dysfunction is commonly regarded as a key event in atherogenesis. Lycopene, at physiological concentrations, can protect endothelial cells from oxidative damage induced by hydrogen peroxide( Reference Tang, Yang and Peng 71 ). Lycopene also inhibits cytokine-induced adhesion molecule expression and monocyte–endothelium interactions( Reference Hung, Huang and Chen 72 ). Inhibition of agonist-stimulated platelet aggregation have also been observed at physiologically relevant concentrations( Reference Hsiao, Wang and Tzu 73 , Reference Sawardekar, Patel and Uchil 74 ). Experiments carried out in THP-1 (a human monocytic leukemia cell line) macrophages showed that lycopene can inhibit cholesterol synthesis as well as scavenger receptor expression, which suggests that it could potentially modulate foam cell formation( Reference Palozza, Simone and Catalano 75 , Reference Napolitano, De Pascale and Wheeler-Jones 76 ).

Lycopene has potent antioxidant chemical properties, and therefore much interest has focused on its potential ability to inhibit LDL oxidation, which is central to the initiation of atherosclerosis. The outcomes of such studies largely depend on the conditions used to oxidise the LDL particles. However, considering the very central position of lycopene within the core of LDL particles, it is unlikely that lycopene under normal physiological conditions can effectively protect LDL from oxidation( Reference Müller, Caris-veyrat and Lowe 77 ).

Atherosclerosis has a strong inflammatory component. The anti-inflammatory properties of lycopene have been tested using various relevant cell culture models, including macrophages, foam cells and smooth muscle cells and the outcomes of such studies have been previously reviewed( Reference Palozza, Parrone and Simone 70 ). Overall, results suggest that lycopene can neutralise reactive oxygen species, as well as reduce the secretion of pro-inflammatory cytokines and metalloproteinases by macrophages( Reference Marcotorchino, Romier and Gouranton 78 , Reference Zou, Feng and Ling 79 ), inhibit smooth muscle cell proliferation( Reference Lo, Hung and Tseng 80 ) and decrease monocyte proliferation( Reference McDevitt, Tchao and Harrison 81 ). More recently, work in our group showed that low, physiological concentrations of lycopene can significantly inhibit mitogen-activated T lymphocyte activation by modulating mechanisms involved in early activation( Reference Mills, Wilson and Thies 82 ). Lycopene significantly inhibited mitogen-activated lymphocyte proliferation by up to 40 % and also significantly inhibited the expression of an early marker of activation, CD69, as well as IL-2 secretion. However, IL-2 receptor expression and cell-cycle profile were unaffected by lycopene. T lymphocytes are an active component of the chronic inflammatory process during atherogenesis. A reduction in T-cell activation would reduce the inflammatory responses involved in atherosclerotic plaque formation and development.

Whether lycopene acts directly, or indirectly via oxidised metabolites, still remains to be determined. Food processing-induced or metabolic oxidation of lycopene can lead to the formation of apo-lycopenoids, a family of compounds containing a ketone or an aldehyde function. Particular interest has focused on apo-lycopenals, which can modulate cellular function via the antioxidant response element transcription system( Reference Linnewiel, Ernst and Caris-Veyrat 64 ) and inhibit tumourigenesis( Reference Ford, Elsen and Zuniga 83 ). Apo-10′-lycopenoic acid can also modulate adipocyte activity via the retinoic acid receptors( Reference Gouranton, Thabuis and Riollet 84 ).

Interestingly, lycopene has recently been found to reduce the formation of advanced glycation end products in HK-2 cells and in rat kidneys, which led to a concomitant decrease in the expression of their receptors and NF-κB and matrix metalloproteinase 2( Reference Tabrez, Al-Shali and Ahmad 85 ). Advanced glycation end products and the activation of their receptors lead to oxidative stress and inflammation, and enhanced generation and accumulation of advanced glycation end products have been associated with increased risk for cardiovascular complications associated with atherosclerosis and diabetes( Reference Stirban, Gawlowski and Roden 86 ). The inhibition of these processes by lycopene could therefore represent additional mechanisms by which lycopene can protect against CVD and related disorders.

Intervention trials

Human intervention studies related to the cardioprotective effects of lycopene have given mixed results. The majority (thirty-five) of fifty-four intervention trials using lycopene supplements or tomato-based products carried out between 1998 and 2010 found beneficial effects on CVD risk markers( Reference Mordente, Guantario and Meucci 87 ). However, only thirteen studies included conventional markers of CVD (such as blood pressure, CRP and serum cholesterol concentrations) of which only five showed beneficial effects. The majority of studies (thirty-one out of forty-nine), which included non-established markers for CVD risk, such as lipid peroxidation, DNA damage, LDL oxidation, platelet activation and inflammatory markers other than CRP, showed some benefits of increasing lycopene intake. Unfortunately, the search strategy was not provided and the quality of the study design was not assessed in that review. Most of the studies lacked statistical power as they usually included a relatively low number of volunteers (below 100). The majority of the trials (forty-three out of forty-nine) were also of short duration (up to 30 d) and some were poorly controlled. The sources of lycopene (supplements, tomato juice, soup, puree or tomato extract) as well as the daily dose provided (from 5 to 80 mg) also varied considerably between studies, making comparison between trials difficult.

Comparison of efficacy between tomato intake and lycopene supplementation in modifying CVD risk factors was also recently reviewed( Reference Burton-Freeman and Sesso 26 ). The authors included studies reporting effects on LDL oxidation, various markers of oxidative stress and damage, inflammatory markers, endothelial function, blood pressure and serum lipid concentrations. Overall, and despite the heterogeneity of results, growing evidence suggests that increasing lycopene intake from tomato products would be more effective compared with supplements for improving serum lipids, protein and DNA damage and some inflammatory markers including CRP, whereas lycopene supplementation seems to be more effective in reducing blood pressure compared with tomato-based foods. The reason behind this disparity is unclear. Tomatoes contain other components such as ascorbic acid, potassium and a range of bioactive phytochemicals such as tomatine, a steroidal glycoalkaloid and its metabolite, tomatidine, which could also provide health benefits( Reference Friedman 17 ). However, it is possible that some of these compounds interfere with the hypotensive effect of lycopene. Only a few trials reported on blood pressure (five supplementation trials and three tomato studies), which is insufficient to draw any substantial conclusion. The mechanisms by which lycopene could modulate blood pressure remain also to be elucidated.

A recent pilot study carried out in forty heart failure patients (twenty-three men, seventeen women) showed that the daily consumption of 29·4 mg lycopene (one can daily of V8 juice) for 30 d significantly reduced serum CRP concentrations in women only, while compliance to the intervention seemed similar between men and women( Reference Biddle, Lennie and Bricker 88 ). The effect of lycopene supplementation (7 mg daily over 2 months) on vascular function was recently assessed in healthy volunteers and statin-treated CVD patients in a randomised, placebo-controlled, double-blind intervention trial( Reference Gajendragadkar, Hubsch and Maki-Petaja 89 ). Lycopene supplementation significantly improved endothelial-dependant arterial vasodilation by 53 % in patients under optimal secondary prevention treatment, but had no effect in healthy volunteers. These results suggest that lycopene supplementation could positively modify cardiovascular outcomes in high-risk populations and could increase the efficacy of secondary prevention pharmacological treatment for heart disease.

In 144 patients with sub-clinical atherosclerosis, as assessed by the measurement of carotid artery intima-media thickness, lycopene supplementation (20 mg/d) for 12 months significantly improved the efficacy of lutein supplementation (20 mg/d) to decrease carotid artery intima-media thickness (0·035 mm decrease with lutein supplementation alone v. 0·073 mm decrease with both lutein and lycopene supplementation( Reference Zou, Xu and Lin 90 )). These results suggest a synergistic effect between lutein and lycopene. However, this trial should have ideally also included a group receiving lycopene only to confirm whether the larger decrease was due to the combination of lutein and lycopene or lycopene alone. Whether the magnitude of reduction of carotid artery intima-media thickness observed is clinically relevant needs to be evaluated with the inclusion of other risk factors, as meta-analyses suggest that carotid artery intima-media thickness alone only minimally improves disease-risk predictive power beyond traditional risk factors( Reference Naqvi and Lee 91 ).

The first worldwide comprehensive, well-controlled, randomised trial aiming to determine whether increased lycopene consumption, from supplement or high tomato diet, can modulate markers of CVD risk was carried out in the UK a few years ago( Reference Thies, Masson and Rudd 21 ). After a 4-week run-in period with a low-tomato diet, 225 volunteers (ninety-four men and 131 women) aged 40–65 years were randomly assigned into one of three dietary intervention groups and asked to consume a control diet (low in tomato-based foods), a high-tomato-based diet (35–50 mg lycopene/d), or a control diet supplemented with lycopene capsules (10 mg/d) for 12 weeks. Despite excellent compliance in all treatment groups, none of the systemic markers (inflammatory markers, markers of insulin resistance and sensitivity, lipid concentrations) significantly changed after the dietary intervention. Blood pressure and arterial stiffness were also unaffected by the treatments, indicating that increased lycopene intake, from supplement or from a tomato based-rich diet, is ineffective at reducing conventional CVD risk markers in the population considered. However, in order to identify novel potential markers for cardiovascular risk modifiable by lycopene, the authors examined the effect of the intervention on HDL-functionality and HDL-associated inflammation in a subgroup of participants (eighteen per treatment group). The results showed that increased lycopene intake using supplements or by dietary means over 12 weeks reduced serum amyloid A content in serum and HDL3 ( Reference McEneny, Wade and Young 92 ). These changes were associated with a concomitant improvement in HDL functionality, as measured by the activity of HDL-associated enzymes such as paraoxonase 1, lecithin cholesterol acyl transferase and cholesterol ester transfer protein, potentially enhancing HDL-antiatherogenic properties.


The integrated potential mechanisms involved in the antiatherogenic effects of lycopene are summarised in Fig. 2. Despite some discrepancies between observational and intervention studies, the evidence for cardioprotective effects of lycopene is increasing. The recent discovery of novel mechanisms by which lycopene could exert its beneficial effects also warrant further research, and also suggest novel biomarkers for cardiovascular risk such as HDL functionality, susceptible to modification by dietary intervention. The identification of specific genetic patterns linked to interindividual variability in lycopene bioavailability also highlights the requirement for further research to understand how genotype modifies the cardiovascular benefits of lycopene.

Fig. 2. Integrated mechanisms potentially responsible for the antiatherogenic effects of lycopene: Lycopene may inhibit endothelial injury, inhibit cholesterol synthesis, inhibit LDL oxidation, restore HDL functionality, inhibit proinflammatory activity driven by macrophages and T lymphocytes, inhibit foam cell formation and inhibit smooth muscle cell proliferation. ABC's, ATP-binding cassette transporters; AGE, advanced glycation end products; MMP, metalloproteinases; RAGE, receptor for advanced glycation end products; SMC, smooth muscle cells.


F. T. and S. M. are grateful for support from the Scottish Government (Rural and Environmental Science and Analytical Services).

Financial Support

F. T. and L. F. M. received funding from the UK Food Standard Agency for tomato and lycopene-related research.

Conflict of Interest



F. T. presented the work and drafted the manuscript. F. T., L. M. M., S. M. and L. F. M. researched and contributed to sections for the manuscript. All authors reviewed the manuscript prior to submission.


1. Trichopoulou, A, Costacou, T, Bamia, C et al. (2003) Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 348, 25992608.CrossRefGoogle Scholar
2. Agudo, A, Cabrera, L, Amiano, P et al. (2007) Fruit and vegetable intakes, dietary antioxidant nutrients, and total mortality in Spanish adults: findings from the Spanish cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Spain). Am J Clin Nutr 85, 16341642.CrossRefGoogle ScholarPubMed
3. Nicklett, EJ, Semba, RD, Xue, QL et al. (2012) Fruit and vegetable intake, physical activity, and mortality in older community dwelling women. J Am Geriatr Soc 60, 862868.CrossRefGoogle ScholarPubMed
4. Wang, X, Ouyang, Y, Liu, J et al. (2014) Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ 349, g4490.CrossRefGoogle ScholarPubMed
5. Maiani, G, Casto´n, MJ, Catasta, G et al. (2009) Carotenoids: actual knowledge on food sources, intakes, stability and bioavailability and their protective role in humans. Mol Nutr Food Res 53, Suppl. 2, S194S218.CrossRefGoogle ScholarPubMed
6. Zu, K, Mucci, L, Rosner, BA et al. (2014) Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst 106, djt430.CrossRefGoogle ScholarPubMed
7. Giovannucci, E, Ascherio, A, Rimm, EB et al. (1995) Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 87, 17671776.CrossRefGoogle ScholarPubMed
8. Giovannucci, E, Rimm, EB, Liu, Y et al. (2002) A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 94, 391398.CrossRefGoogle ScholarPubMed
9. Sesso, HD, Liu, S, Gaziano, JM et al. (2003) Dietary lycopene, tomato-based food products and cardiovascular disease in women. J Nutr 133, 23362341.CrossRefGoogle ScholarPubMed
10. Clinton, SK (1998) Lycopene: chemistry, biology, and implications for human health and disease. Nutr Rev 56, 3551.CrossRefGoogle ScholarPubMed
11. Rao, AV, Ray, MR & Rao, LG (2006) Lycopene. Adv Food Nutr Res 51, 99164.CrossRefGoogle ScholarPubMed
12. Ganji, V & Kafai, MR (2005) Population determinants of serum lycopene concentrations in the United States: data from the Third National Health and Nutrition Examination Survey, 1988–1994. J Nutr 135, 567572.CrossRefGoogle ScholarPubMed
13. Allen, CM, Schwartz, SJ, Craft, NE et al. (2003) Changes in plasma and oral mucosal lycopene isomer concentrations in healthy adults consuming standard servings of processed tomato products. Nutr Cancer 47, 4856.CrossRefGoogle ScholarPubMed
14. Re, R, Mishra, GD, Thane, CW et al. (2003) Tomato consumption and plasma lycopene concentration in people aged 65 y and over in a British national survey. Eur J Clin Nutr 57, 15451554.CrossRefGoogle Scholar
15. Erdman, JW Jr, Ford, NA & Lindshield, BL (2009) Are the health attributes of lycopene related to its antioxidant function? Arch Biochem Biophys 483, 229235.CrossRefGoogle ScholarPubMed
16. Jenab, M, Ferrari, P, Mazuir, M et al. (2005) Variations in lycopene blood levels and tomato consumption across European countries based on the European Prospective Investigation into Cancer and Nutrition (EPIC) study. J Nutr 135, 2032S2036S.CrossRefGoogle ScholarPubMed
17. Friedman, M (2013) Anticarcinogenic, cardioprotective, and other health benefits of tomato compounds lycopene, α-tomatine, and tomatidine in pure form and in fresh and processed tomatoes. J Agric Food Chem 61, 95349550.CrossRefGoogle ScholarPubMed
18. Di Mascio, P, Kaiser, S & Sies, H (1989) Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 274, 532538.CrossRefGoogle ScholarPubMed
19. Pennathur, S, Maitra, D, Byun, J et al. (2010) Antioxidative activity of lycopene: a potential role in scavenging hypochlorous acid. Free Radic Biol Med 49, 205213.CrossRefGoogle ScholarPubMed
20. Porrini, M & Riso, P (2005) What are typical lycopene intakes? J Nutr 135, 2042S2045S.CrossRefGoogle ScholarPubMed
21. Thies, F, Masson, LF, Rudd, A et al. (2012) Effect of a tomato-rich diet on markers of cardiovascular disease risk in moderately overweight, disease-free, middle-aged adults: a randomized controlled trial. Am J Clin Nutr 102, 14361449.Google Scholar
22. Jacques, PF, Lyass, A, Massaro, JM et al. (2013) relation of lycopene intake and consumption of tomato products to incident cardiovascular disease. Br J Nutr 110, 545551.CrossRefGoogle Scholar
23. Lucarini, M, Lanzi, S, D'Evoli, L et al. (2006) Intake of vitamin A and carotenoids from the Italian population–results of an Italian total diet study. Int J Vitam Nutr Res 76, 103109.CrossRefGoogle ScholarPubMed
24. Schierle, J, Bretzel, W, Buhler, I et al. (1997) Content and isomeric ratio of lycopene in food and human blood plasma. Food Chem 59, 459465.CrossRefGoogle Scholar
25. Walfisch, Y, Walfisch, S, Agbaria, R et al. (2003) Lycopene in serum, skin and adipose tissues after tomato-oleoresin supplementation in patients undergoing haemorrhoidectomy or peri-anal fistulotomy. Br J Nutr 90, 759766.CrossRefGoogle ScholarPubMed
26. Burton-Freeman, BM & Sesso, HD (2014) Whole food versus supplement: comparing the clinical evidence of tomato intake and lycopene supplementation on cardiovascular risk factors. Adv Nutr 5, 457485.CrossRefGoogle ScholarPubMed
27. Re, R, Fraser, PD, Long, M et al. (2001) Isomerization of lycopene in the gastric milieu. Biochem Biophys Res Commun 281, 576578.CrossRefGoogle ScholarPubMed
28. Richelle, M, Sanchez, B, Tavazzi, I et al. (2010) Lycopene isomerisation takes place within enterocytes during absorption in human subjects. Br J Nutr 10, 18001807.CrossRefGoogle Scholar
29. Teodoro, AJ, Perrone, D, Martucci, RB et al. (2009) Lycopene isomerisation and storage in an in vitro model of murine hepatic stellate cells. Eur J Nutr 48, 261268.CrossRefGoogle Scholar
30. Moussa, M, Landrier, JF, Reboul, E et al. (2008) Lycopene absorption in human intestinal cells and in mice involves scavenger receptor class B type I but not Niemann–Pick C1-like 1. J Nutr 138, 14321436.CrossRefGoogle Scholar
31. Moussa, M, Gouranton, E, Gleize, B et al. (2011) CD36 is involved in lycopene and lutein uptake by adipocytes and adipose tissue cultures. Mol Nutr Food Res 55, 578584.CrossRefGoogle ScholarPubMed
32. Ferrucci, L, Perry, JR, Matteini, A et al. (2009) Common variation in the beta-carotene 15,15′ monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. Am J Hum Genet 84, 123133.CrossRefGoogle ScholarPubMed
33. Lindshield, BL, Canene-Adams, K & Erdman, JW Jr (2007) Lycopenoids: are lycopene metabolites bioactive? Arch Biochem Biophys 458, 136140.CrossRefGoogle ScholarPubMed
34. Ross, AB, Vuong le, T, Ruckle, J et al. (2011) Lycopene bioavailability and metabolism in humans: an accelerator mass spectrometry study. Am J Clin Nutr 93, 12631273.CrossRefGoogle ScholarPubMed
35. Moran, NE, Cichon, MJ, Riedl, KM et al. (2015) Compartmental and noncompartmental modelling of 13C-lycopene absorption, isomerization and distribution kinetics in healthy adults. Am J Clin Nutr 102, 14361449.CrossRefGoogle ScholarPubMed
36. Rock, CL, Swendseid, ME, Jacob, RA et al. (1992) Plasma carotenoid levels in human subjects fed a low carotenoid diet. J Nutr 122, 96100.CrossRefGoogle ScholarPubMed
37. Borel, P, Desmarchelier, C, Nowicki, M et al. (2015) Lycopene bioavailability is associated with a combination of genetic variants. Free Rad Biol Med 83, 238244.CrossRefGoogle ScholarPubMed
38. Zubair, N, Kooperberg, C, Liu, J et al. (2015) Genetic variation predicts serum lycopene concentrations in a multiethnic population of postmenopausal women. J Nutr 145, 187192.CrossRefGoogle Scholar
39. Rissanen, TH, Voutilainen, S, Nyyssonen, KI et al. (2001) Low serum lycopene concentration is associated with an excess incidence of acute coronary events and stroke: the Kuopio Ischaemic Heart Disease Risk Factor Study. Br J Nutr 85, 749754.CrossRefGoogle ScholarPubMed
40. Sesso, HD, Buring, JE, Norkus, EP et al. (2004) Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women. Am J Clin Nutr 79, 4753.CrossRefGoogle ScholarPubMed
41. Yeo, HY, Kim, OY, Lim, HH et al. (2011) Association of serum lycopene and brachial-ankle pulse wave velocity with metabolic syndrome. Metabolism 60, 537543.CrossRefGoogle ScholarPubMed
42. Karppi, J, Kurl, S, Ronkainen, K et al. (2013) Serum carotenoids reduce progression of early atherosclerosis in the carotid artery wall among eastern Finnish men. PLoS ONE 8, e64107.CrossRefGoogle ScholarPubMed
43. Karppi, J, Laukkanen, JA, Sivenius, J et al. (2012) Serum lycopene decreases the risk of stroke in men. Neurology 79, 15401547.CrossRefGoogle ScholarPubMed
44. Wang, Y, Chung, SJ, McCullough, ML et al. (2014) Dietary carotenoids are associated with cardiovascular disease risk biomarkers mediated by serum carotenoid concentrations. J Nutr 144, 10671074.CrossRefGoogle ScholarPubMed
45. Ascherio, A, Rimm, EB, Hernan, MA et al. (1999) Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States. Ann Intern Med 130, 963970.CrossRefGoogle ScholarPubMed
46. Hirvonen, T, Virtamo, J, Korhonen, P et al. (2000) Intake of flavonoids, carotenoids, vitamins C and E, and risk of stroke in male smokers. Stroke 31, 23012306.CrossRefGoogle Scholar
47. Osganian, SK, Stampfer, MJ, Rimm, E et al. (2003) Dietary carotenoids and risk of coronary artery disease in women. Am J Clin Nutr 77, 13901399.CrossRefGoogle ScholarPubMed
48. Tavani, A, Gallus, S, Negri, E et al. (2006) Dietary intake of carotenoids and retinol and the risk of acute myocardial infarction in Italy. Free Radic Res 40, 659664.CrossRefGoogle ScholarPubMed
49. Li, X & Xu, J (2014) Dietary and circulating lycopene and stroke risk: a meta-analysis of prospective studies. Sci Rep 4, 5031.CrossRefGoogle Scholar
50. Kelkel, M, Schumacher, M, Dicato, M et al. (2011) Antioxidant and anti-proliferative properties of lycopene. Free Radic Res 45, 925940.CrossRefGoogle ScholarPubMed
51. Feitelson, MA, Arzumanyan, A, Kulathinal, RJ et al. (2015) Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin Cancer Biol 35, S25S54.CrossRefGoogle ScholarPubMed
52. Amir, H, Karas, M, Giat, J et al. (1999) Lycopene and 1,25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Nutr Cancer 33, 105112.CrossRefGoogle ScholarPubMed
53. Gupta, P, Bansal, MP & Koul, A (2013) Evaluating the effect of lycopene from Lycopersicum esculentum on apoptosis during NDEA induced hepatocarcinogenesis. Biochem Biophys Res Commun 434, 479485.CrossRefGoogle ScholarPubMed
54. Uppala, PT, Dissmore, T, Lau, BHS et al. (2013) Selective inhibition of cell proliferation by lycopene in MCF-7 breast cancer cells in vitro: a proteomic analysis. Phytother Res 27, 595601.CrossRefGoogle ScholarPubMed
55. Agca, CA, Tuzcu, M, Gencoglu, H et al. (2012) Lycopene counteracts the hepatic response to 7,12 dimethylbenz[a]anthracene by altering the expression of Bax, Bcl-2, caspases, and oxidative stress biomarkers. Pharm Biol 50, 15131518.CrossRefGoogle Scholar
56. Chalabi, N, Delort, L, Le Corre, L et al. (2006) Gene signature of breast cancer cell lines treated with lycopene. Pharmacogenomics 7, 663672.CrossRefGoogle ScholarPubMed
57. Stahl, W, von Laar, J, Martin, HD et al. (2000) Stimulation of gap junctional communication: comparison of acyclo-retinoic acid and lycopene. Arch Biochem Biophys 373, 271274.CrossRefGoogle ScholarPubMed
58. Palozza, P, Simone, RE, Catalano, A et al. (2011) Tomato lycopene and lung cancer prevention: from experimental to human studies. Cancers 3, 23332357.CrossRefGoogle ScholarPubMed
59. Palozza, P, Simone, R, Catalano, A et al. (2012) Lycopene modulation of molecular targets affected by smoking exposure. Curr Cancer Drug Targets 12, 640657.CrossRefGoogle ScholarPubMed
60. Chen, ML, Lin, YH, Yang, CM et al. (2012) Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3 K-Akt and ERK/p38 signaling pathways. Mol Nutr Food Res 56, 889899.CrossRefGoogle Scholar
61. Huang, CS, Chuang, CH, Lo, TF et al. (2013) Antiangiogenic effects of lycopene through immunomodualtion of cytokine secretion in human peripheral blood mononuclear cells. J Nutr Biochem 24, 428434.CrossRefGoogle ScholarPubMed
62. Lian, F & Wang, XD (2008) Enzymatic metabolites of lycopene induce Nrf2-mediated expression of phase II detoxifying/antioxidant enzymes in human bronchial epithelial cells. Int J Cancer 123, 12621268.CrossRefGoogle ScholarPubMed
63. Sahin, K, Tuzcu, M, Sahin, N et al. (2010) Nrf2/HO-1signaling pathway may be the prime target for chemoprevention of cisplatin-induced nephrotoxicity by lycopene. Food Chem Toxicol 48, 26702674.CrossRefGoogle Scholar
64. Linnewiel, K, Ernst, H, Caris-Veyrat, C et al. (2009) Structure activity relationship of carotenoid derivatives in activation of the electrophile/antioxidant response element transcription system. Free Radic Biol Med 47, 659667.CrossRefGoogle ScholarPubMed
65. Herzog, A, Siler, U, Spitzer, V et al. (2005) Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J 19, 272274.CrossRefGoogle ScholarPubMed
66. Aydemir, G, Kasiri, Y, Birta, E et al. (2014) Lycopene-derived bioactive retinoic acid receptors/retinoid-X receptors-activating metabolites may be relevant for lycopene's anti-cancer potential. Mol Nutr Food Res 57, 739747.CrossRefGoogle Scholar
67. Tan, HL, Moran, NE, Cichon, MJ et al. (2014) β-Carotene-9′,10′-oxygenase status modulates the impact of dietary tomato and lycopene on hepatic nuclear receptor-, stress-, and metabolism-related gene expression in mice. J Nutr 144, 43439.CrossRefGoogle ScholarPubMed
68. Stahl, W & Sies, H (2012) Photoprotection by dietary carotenoids: concept, mechanisms, evidence and future development. Mol Nutr Food Res 56, 287295.CrossRefGoogle ScholarPubMed
69. Aydemir, G, Kasiri, Y, Bartók, EM et al. (2016) Lycopene supplementation restores vitamin A deficiency in mice and possesses thereby partial pro-vitamin A activity transmitted via RAR-signaling. Mol Nutr Food Res. (Epublication ahead of print version).CrossRefGoogle ScholarPubMed
70. Palozza, P, Parrone, N, Simone, RE et al. (2010) Lycopene in atherosclerosis prevention: an integrated scheme of the potential mechanisms of action from cell culture studies. Arch Biochem Biophys 504, 2633.CrossRefGoogle ScholarPubMed
71. Tang, X, Yang, X, Peng, Y et al. (2009) Protective effects of lycopene against H2O2-induced oxidative injury and apoptosis in human endothelial cells. Cardiovasc Drugs Ther 23, 439448.CrossRefGoogle ScholarPubMed
72. Hung, CF, Huang, TF, Chen, BH et al. (2008) Lycopene inhibits TNF-alpha-induced endothelial ICAM-1 expression and monocyte-endothelial adhesion. Eur J Pharmacol 586, 275282.CrossRefGoogle ScholarPubMed
73. Hsiao, G, Wang, Y, Tzu, NH et al. (2005) Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation. J Lab Clin Med 146, 216226.CrossRefGoogle ScholarPubMed
74. Sawardekar, SB, Patel, TC & Uchil, D (2016) Comparative evaluation of antiplatelet effect of lycopene with aspirin and the effect of their combination on platelet aggregation: an in vitro study. Indian J Pharmacol 48, 2631.CrossRefGoogle ScholarPubMed
75. Palozza, P, Simone, R, Catalano, A et al. (2011) Lycopene regulation of cholesterol synthesis and efflux in human macrophages. J Nutr Biochem 22, 971978.CrossRefGoogle ScholarPubMed
76. Napolitano, M, De Pascale, C, Wheeler-Jones, et al. (2007) Effects of lycopene on the induction of foam cell formation by modified LDL. Am J Physiol Endocrinol Metab 293, E1820E1827.CrossRefGoogle ScholarPubMed
77. Müller, L, Caris-veyrat, C, Lowe, G et al. (2015) Lycopene and its antioxidant role in the prevention of cardiovascular diseases – a critical review. Crit Rev Food Sci Nutr 56, 18681879.CrossRefGoogle Scholar
78. Marcotorchino, J, Romier, B, Gouranton, E et al. (2012) Lycopene attenuates LPS-induced TNF-α secretion in macrophages and inflammatory markers in adipocytes exposed to macrophage-conditioned media. Mol Nutr Food Res 56, 725732.CrossRefGoogle ScholarPubMed
79. Zou, J, Feng, D, Ling, WH et al. (2013) Lycopene suppresses proinflammatory response in lipopolysaccharide-stimulated macrophages by inhibiting ROS-induced trafficking of TLR4 to lipid raft-like domains. J Nutr Biochem 24, 11171122.CrossRefGoogle ScholarPubMed
80. Lo, HM, Hung, CF, Tseng, YL et al. (2007) Lycopene binds PDGF-BB and inhibits PDGF-BB-induced intracellular signaling transduction pathway in rat smooth muscle cells. Biochem Pharmacol 74, 5463.CrossRefGoogle ScholarPubMed
81. McDevitt, TM, Tchao, R, Harrison, EH et al. (2005) Carotenoids normally present in serum inhibit proliferation and induce differentiation of a human monocyte/macrophage cell line (U937). J Nutr 135, 160164.CrossRefGoogle ScholarPubMed
82. Mills, L, Wilson, H & Thies, F (2012) Lycopene inhibits lymphocyte proliferation through mechanisms dependent on early cell activation. Mol Nutr Food Res 56, 10341042.CrossRefGoogle ScholarPubMed
83. Ford, NA, Elsen, AC, Zuniga, K et al. (2011) Lycopene and apo-12′-lycopenal reduce cell proliferation and alter cell cycle progression in human prostate cancer cells. Nutr Cancer 63, 256263.CrossRefGoogle ScholarPubMed
84. Gouranton, E, Thabuis, C, Riollet, C et al. (2011) Lycopene inhibits proinflammatory cytokine and chemokine expression in adipose tissue. J Nutr Biochem 22, 642648.CrossRefGoogle ScholarPubMed
85. Tabrez, S, Al-Shali, KZ & Ahmad, S (2015) Lycopene powers the inhibition of glycation-induced diabetic nephropathy: a novel approach to halt the AGE-RAGE axis menace. Biofactors 41, 372381.CrossRefGoogle ScholarPubMed
86. Stirban, A, Gawlowski, T & Roden, M (2014) Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms. Mol Metab 3, 94108.CrossRefGoogle ScholarPubMed
87. Mordente, A, Guantario, B, Meucci, E et al. Lycopene and cardiovascular diseases: an update. Curr Med Chem 18, 11461163.CrossRefGoogle Scholar
88. Biddle, MJ, Lennie, TR, Bricker, GV et al. (2016) Lycopene dietary intervention: a pilot study in patients with heart failure. Cardiovasc Nurs 30, 205212.CrossRefGoogle Scholar
89. Gajendragadkar, PR, Hubsch, A, Maki-Petaja, KM et al. (2014) Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy Volunteers: a randomised controlled trial. PLoS ONE 9, e99070.CrossRefGoogle ScholarPubMed
90. Zou, ZY, Xu, XR, Lin, XM et al. (2014) Effects of lutein and lycopene on carotid intima–media thickness in Chinese subjects with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Br J Nutr 111, 474480.CrossRefGoogle ScholarPubMed
91. Naqvi, TZ & Lee, MS (2014) Carotid intima-media thickness and plaque in cardiovascular risk assessment. J Am Coll Cardiol Img 7, 10251038.CrossRefGoogle ScholarPubMed
92. McEneny, J, Wade, L, Young, IS et al. (2013) Lycopene reduces inflammation and improves HDL functionality in moderately overweight middle aged individuals. J Nutr Biochem 24, 163168.CrossRefGoogle ScholarPubMed
Figure 0

Fig. 1. Potential mechanisms by which lycopene can modulate cellular activity.

Figure 1

Fig. 2. Integrated mechanisms potentially responsible for the antiatherogenic effects of lycopene: Lycopene may inhibit endothelial injury, inhibit cholesterol synthesis, inhibit LDL oxidation, restore HDL functionality, inhibit proinflammatory activity driven by macrophages and T lymphocytes, inhibit foam cell formation and inhibit smooth muscle cell proliferation. ABC's, ATP-binding cassette transporters; AGE, advanced glycation end products; MMP, metalloproteinases; RAGE, receptor for advanced glycation end products; SMC, smooth muscle cells.